Back to top
more

BioXcel Therapeutics (BTAI)

(Real Time Quote from BATS)

$2.74 USD

2.74
12,614

-0.01 (-0.36%)

Updated Apr 16, 2024 10:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

BioXcel Therapeutics, Inc. [BTAI]

Reports for Purchase

Showing records 21 - 40 ( 106 total )

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

05/23/2022

Company Report

Pages: 5

TRANQUILITY II Pivotal Trial Starts; 1Q22 Financials; Lowering PT to $110

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

04/14/2022

Company Report

Pages: 5

IGALMI Approval on Schedule; Launch Near-Term; Raising PT to $134

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

03/14/2022

Company Report

Pages: 4

BXCL501 Approval Decision Nears; 2021 Financials; Adjusting PT to $130

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

12/16/2021

Company Report

Pages: 5

BXCL501 Alzheimer''s Disease Pivotal Program Initiated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

12/02/2021

Company Report

Pages: 5

BXCL501 Approval Decision Date Delayed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

11/11/2021

Company Report

Pages: 6

BXCL501 Dementia Pivotal Trial Start Nears; 3Q21 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

10/19/2021

Company Report

Pages: 6

BXCL701 Clinical Trial Expansion; Pipeline Widens; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for BTAI

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

09/17/2021

Company Report

Pages: 5

BXCL701 Prostate Cancer Clinical Data Presented; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

08/11/2021

Company Report

Pages: 5

All Eyes on BXCL501; 2Q21 Financial Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

06/28/2021

Company Report

Pages: 5

Commercial Day Perspectives; Cash Replenished; Lowering PT to $140

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

06/01/2021

Company Report

Pages: 4

BXCL501 New Drug Application Accepted for Review; Raising PT to $176

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

05/11/2021

Company Report

Pages: 5

BXCL501 NDA Review; Delirium Trial Paused; 1Q21 Financials; PT Lowered to $170

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

04/01/2021

Company Report

Pages: 5

BXCL501 RELEASE Trial Yields Mixed Results; Reducing PT to $175

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

03/16/2021

Company Report

Pages: 5

BXCL501 Gets Breakthrough Therapy Designation in Dementia; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

03/15/2021

Company Report

Pages: 5

Focus Shifting to Market Strategy; 2020 Financial Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

03/11/2021

Company Report

Pages: 5

BXCL501 Submitted to FDA; Multiple Near-Term Catalysts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

03/08/2021

Company Report

Pages: 5

Dementia Clinical Development Clarity; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

01/27/2021

Company Report

Pages: 5

BXCL701 Orphan Drug Status Granted in Soft Tissue Sarcoma; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

01/20/2021

Daily Note

Pages: 33

Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party